The sequence of docetaxel‐cabazitaxel‐enzalutamid in men with metastatic castration‐resistant prostate cancer

02/2018

MUDr. Ivo Kocák, Ph.D.1, MUDr. Zdenek Řehák, Ph.D.2

1) Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

2) Oddělení nukleární medicíny, Masarykův onkologický ústav, Brno

 

SUMMARY

In the present case, we present a possible sequential treatment for metastatic castration-resistant prostate cancer into the skeleton (mCRPC). Because of symptomatic disease, chemotherapy therapy has been launched that has been able to effectively reduce the symptoms of the disease. The tolerance of the docetaxel-cabazitaxel sequence was very good. Once the chemotherapy options have been exhausted, ARTA treatment with enzalutamide has been chosen, which further effectively stabilizes the disease, maintains overall good status. Sequential treatment of mCRPC has lasted nearly 4 years.

 

KEY WORDS

metastatic castration-resistant prostate cancer, docetaxel, cabazitaxel, enzalutamid

 

 

Celý článek je dostupný pouze pro předplatitele

Staňte se pravidelným odběratelem našeho časopisu Onkologická revue...

 

VÍCE O PŘEDPLATNÉM